Literature DB >> 26302495

Incidentally Identified Common Bile Duct Dilatation: A Systematic Review of Evaluation, Causes, and Outcome.

Ioana Smith1, Klaus Monkemuller, C Mel Wilcox.   

Abstract

BACKGROUND: With the widespread use of abdominal imaging, an incidentally found dilated common bile duct (CBD) is a common radiographic finding. The significance of a dilated CBD as a predictor of underlying disease and long-term outcome have not been well elucidated. GOALS: A systematic review of studies on patients with dilated CBD was performed to identify etiologies and clinical factors that may predict which patients require further diagnostic testing and long-term outcomes. A PubMed search for relevant articles published between 2001 and 2014 was performed.
RESULTS: The search yielded a total of 882 articles, and after careful individual review for eligibility and relevancy, 9 peer-reviewed studies were included. A cause of the CBD dilation was found on average in 33% of cases and the most common causes were: CBD stone, chronic pancreatitis, and periampullary diverticulum. The overall CBD diameter was not associated with finding a causative lesion. Coexisting CBD and intrahepatic bile duct dilation, age, and jaundice were found to be indicators of pathologic lesions. Dilation of both the CBD and pancreatic duct was suggestive of pancreatic disease, especially pancreatic malignancy in the setting of obstructive jaundice. Follow-up was reported in 6 studies ranging from 6 to 85 months, and generally there was no change in the diagnosis.
CONCLUSIONS: Incidentally found biliary tract dilatation can be a manifestation of significant biliary tract disease including malignancy. Long-term outcome is not well defined and further prospective studies examining the most cost-effective approach to evaluation are needed.

Entities:  

Mesh:

Year:  2015        PMID: 26302495     DOI: 10.1097/MCG.0000000000000394

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  Utilizing CT to identify clinically significant biliary dilatation in symptomatic post-cholecystectomy patients: when should we be worried?

Authors:  Imo I Uko; Cecil Wood; Edward Nguyen; Annie Huang; Roberta Catania; Amir A Borhani; Jeanne M Horowitz; Helena Gabriel; Rajesh Keswani; Paul Nikolaidis; Frank H Miller; Linda C Kelahan
Journal:  Abdom Radiol (NY)       Date:  2022-09-15

2.  [Incidental findings of liver, biliary system, pancreas and spleen in asymptomatic patients : Assessment and management recommendations].

Authors:  M Scharitzer; D Tamandl; A Ba-Ssalamah
Journal:  Radiologe       Date:  2017-04       Impact factor: 0.635

Review 3.  Etiological classification and treatment strategies for secondary bile duct dilatation.

Authors:  Yunfu Lv; Ning Liu; Hongfei Wu; Zhuori Li
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-09

4.  Efficacy of Endoscopic Ultrasonography in Evaluation of Undetermined Etiology of Common Bile Duct Dilatation on Abdominal Ultrasonography.

Authors:  Rasoul Sotoudehmanesh; Naimeh Nejati; Maryam Farsinejad; Shadi Kolahdoozan
Journal:  Middle East J Dig Dis       Date:  2016-10

5.  Role of endoscopic ultrasonography in the diagnostic work-up of idiopathic acute pancreatitis (PICUS): study protocol for a nationwide prospective cohort study.

Authors:  Devica S Umans; Hester C Timmerhuis; Nora D Hallensleben; Stefan A Bouwense; Marie-Paule Gf Anten; Abha Bhalla; Rina A Bijlsma; Marja A Boermeester; Menno A Brink; Lieke Hol; Marco J Bruno; Wouter L Curvers; Hendrik M van Dullemen; Brechje C van Eijck; G Willemien Erkelens; Paul Fockens; Erwin J M van Geenen; Wouter L Hazen; Chantal V Hoge; Akin Inderson; Liesbeth M Kager; Sjoerd D Kuiken; Lars E Perk; Jan-Werner Poley; Rutger Quispel; Tessa Eh Römkens; Hjalmar C van Santvoort; Adriaan Citl Tan; Annemieke Y Thijssen; Niels G Venneman; Frank P Vleggaar; Annet McJ Voorburg; Roy Lj van Wanrooij; Ben J Witteman; Robert C Verdonk; Marc G Besselink; Jeanin E van Hooft
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.